{"id":"cefepim","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Blood coagulation disorder","Colitis","Disorder of brain","Factor II deficiency","Impaired renal function disorder","Myoclonus","Pseudomembranous enterocolitis","Seizure disorder"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT02820987","NCT03687255","NCT03409679","NCT04233996","NCT03680612","NCT00177736","NCT02688582","NCT05535751","NCT04577989","NCT04951505","NCT00435305","NCT01484015","NCT05926063","NCT07072923","NCT07318584","NCT02942810","NCT01543334","NCT05079620","NCT03245879","NCT06748144","NCT05106803","NCT02123628","NCT02680600","NCT07484633","NCT05905055","NCT04278404","NCT06168734","NCT02872038","NCT03078010","NCT05094154","NCT01793012","NCT03790631","NCT02581280","NCT06406114","NCT00044759","NCT03147807","NCT03638830","NCT03680352","NCT03680378","NCT04948463","NCT04033029","NCT01667094","NCT02732327","NCT03622008","NCT02302092","NCT01110408","NCT00609375","NCT00358202","NCT05705843","NCT03685084"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Cefepim","companyId":"university-hospital-tuebingen","ecosystem":[],"mechanism":{"target":"Bacterial penicillin-binding protein","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"University Hospital Tuebingen","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Cefepim","indications":{"approved":[{"name":"Bacterial infection due to Klebsiella pneumoniae","diseaseId":"bacterial-infection-due-to-klebsiella-pneumoniae","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial peritonitis","diseaseId":"bacterial-peritonitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial pneumonia","diseaseId":"bacterial-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial urinary infection","diseaseId":"bacterial-urinary-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Complicated Bacteroides Peritonitis","diseaseId":"complicated-bacteroides-peritonitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Complicated E. Coli Peritonitis","diseaseId":"complicated-e.-coli-peritonitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Complicated Klebsiella Peritonitis","diseaseId":"complicated-klebsiella-peritonitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Complicated Proteus UTI","diseaseId":"complicated-proteus-uti","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Complicated Streptococcus Peritonitis","diseaseId":"complicated-streptococcus-peritonitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Complicated Urinary Tract Infections","diseaseId":"complicated-urinary-tract-infections","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"E. Coli Pyelonephritis","diseaseId":"e.-coli-pyelonephritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Enterobacter Pneumonia","diseaseId":"enterobacter-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Escherichia coli urinary tract infection","diseaseId":"escherichia-coli-urinary-tract-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection due to Pseudomonas aeruginosa","diseaseId":"infection-due-to-pseudomonas-aeruginosa","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection due to Staphylococcus aureus","diseaseId":"infection-due-to-staphylococcus-aureus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infectious disease of abdomen","diseaseId":"infectious-disease-of-abdomen","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Klebsiella Pyelonephritis","diseaseId":"klebsiella-pyelonephritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Klebsiella cystitis","diseaseId":"klebsiella-cystitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumococcal pneumonia","diseaseId":"pneumococcal-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumonia due to Pseudomonas","diseaseId":"pneumonia-due-to-pseudomonas","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumonia due to Streptococcus","diseaseId":"pneumonia-due-to-streptococcus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Proteus Pyelonephritis","diseaseId":"proteus-pyelonephritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Proteus urinary tract infection","diseaseId":"proteus-urinary-tract-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Streptococcus pyogenes infection","diseaseId":"streptococcus-pyogenes-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Urinary tract infection caused by Klebsiella","diseaseId":"urinary-tract-infection-caused-by-klebsiella","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02820987","phase":"Phase 3","title":"Pharmacokinetics and Pharmacodynamic (PK/PD) of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","isPivotal":true,"enrollment":119,"indication":"Septic Shock","completionDate":"2018-10-04"},{"nctId":"NCT03687255","phase":"Phase 3","title":"A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Includin","status":"COMPLETED","sponsor":"Allecra","isPivotal":true,"enrollment":1043,"indication":"Urinary Tract Infections","completionDate":"2020-02-15"},{"nctId":"NCT03409679","phase":"Phase 3","title":"A Multicenter, Open-label, Randomized, Active-controlled, Parallel Group, Pivotal Study to Investigate the Efficacy, Safety and Tolerability, and Pharmacokinetics of Murepavadin Combined With One Anti","status":"TERMINATED","sponsor":"Polyphor Ltd.","isPivotal":true,"enrollment":41,"indication":"Pneumonia","completionDate":"2019-07-17"},{"nctId":"NCT04233996","phase":"Phase 4","title":"Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Haematologic Patients: a Randomised, Multicentre, Open-label, Superiority Clinical Trial (BEATLE)","status":"UNKNOWN","sponsor":"Hospital Universitari de Bellvitge","isPivotal":false,"enrollment":150,"indication":"Febrile Neutropenia","completionDate":"2022-12-31"},{"nctId":"NCT03680612","phase":"Phase 2","title":"Randomized, Double-Blind, Multi-Center Study of Cefepime/AAI101 in Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis","status":"COMPLETED","sponsor":"Allecra","isPivotal":false,"enrollment":45,"indication":"Urinary Tract Infections","completionDate":"2018-02-14"},{"nctId":"NCT00177736","phase":"N/A","title":"Pharmacodynamic Parameters of Two Different Doses of Cefepime","status":"COMPLETED","sponsor":"University of Pittsburgh","isPivotal":false,"enrollment":180,"indication":"Infection, Bacteremia","completionDate":"2007-12"},{"nctId":"NCT02688582","phase":"NA","title":"A Study to Evaluate the Predictive Performance of a Target-controlled Infusion Model for the Administration of Cefepime to Intensive Care Patients","status":"COMPLETED","sponsor":"Onze Lieve Vrouw Hospital","isPivotal":false,"enrollment":21,"indication":"Antimicrobial Treatment","completionDate":"2019-02-28"},{"nctId":"NCT05535751","phase":"N/A","title":"Cefepime vs. Carbapenems for Treating AmpC β-lactamase-producing Enterobacteriaceae Bloodstream Infections","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","isPivotal":false,"enrollment":200,"indication":"Bacteremia","completionDate":"2023-06-20"},{"nctId":"NCT04577989","phase":"N/A","title":"Clinical Comparison of Treatment Strategies in AmpC Beta-lactamase Producing Enterobacterales in a Swiss Tertiary Care Hospital (AmpC-strat Basel)","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","isPivotal":false,"enrollment":270,"indication":"Infection With AmpC Beta-lactamase Producing Enterobacterales","completionDate":"2022-12-19"},{"nctId":"NCT04951505","phase":"Phase 1","title":"A Phase 1 Study to Evaluate the Safety and Intrapulmonary Pharmacokinetics of Cefepime and Taniborbactam in Healthy Subjects","status":"COMPLETED","sponsor":"Venatorx Pharmaceuticals, Inc.","isPivotal":false,"enrollment":30,"indication":"Healthy Subjects","completionDate":"2021-09-27"},{"nctId":"NCT00435305","phase":"N/A","title":"Antibiotic Concentrations in Serum and Epithelial Lining Fluid Under Continous Infusion","status":"TERMINATED","sponsor":"University Hospital Tuebingen","isPivotal":false,"enrollment":40,"indication":"Pneumonia, Bacteremia","completionDate":"2007-11"},{"nctId":"NCT01484015","phase":"Phase 1","title":"Prolonged Infusion Compared to Standard Infusion Cefepime as Empiric Treatment of Febrile Neutropenia: A Pilot Study","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","isPivotal":false,"enrollment":70,"indication":"Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia","completionDate":"2012-10"},{"nctId":"NCT05926063","phase":"Phase 4","title":"Stopping Antibiotics After 3 Days for the Treatment of FEbrile Neutropenia in Haematology Patients (SAFE Study): a Randomized Open-label Non-inferiority Trial","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","isPivotal":false,"enrollment":410,"indication":"Neutropenia, Febrile","completionDate":"2026-07"},{"nctId":"NCT07072923","phase":"Phase 4","title":"Utility of Antibiotic Impregnated Beads in Lower Extremity Osteomyelitis","status":"NOT_YET_RECRUITING","sponsor":"University of Arizona","isPivotal":false,"enrollment":100,"indication":"Osteomyelitis of the Foot, Antibiotic Impregnated Beads","completionDate":"2027-09-30"},{"nctId":"NCT07318584","phase":"Phase 2","title":"Cefotetan Therapy for Escherichia Coli Bacteremia and Genitourinary Infections: a Prospective Phase II Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Oregon Health and Science University","isPivotal":false,"enrollment":84,"indication":"E Coli Infection, ESBL Producing E.Coli","completionDate":"2028-08"},{"nctId":"NCT02942810","phase":"Phase 1","title":"A Phase 1, Open-label, Single-dose Study to Investigate the Pharmacokinetics of Intravenous WCK 5222 (FEP-ZID) in Patients With Renal Impairment","status":"COMPLETED","sponsor":"Wockhardt","isPivotal":false,"enrollment":48,"indication":"Renal Impairment","completionDate":"2017-04"},{"nctId":"NCT01543334","phase":"N/A","title":"Antibiotic Concentrations Among Critically Ill Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","isPivotal":false,"enrollment":98,"indication":"Administration of Antibiotics in Intensive Care Units","completionDate":"2012-04-01"},{"nctId":"NCT05079620","phase":"Phase 4","title":"Antibiotic Prophylaxis in Critically Ill Patients After Suspected Aspiration","status":"TERMINATED","sponsor":"UConn Health","isPivotal":false,"enrollment":5,"indication":"Aspiration, Aspiration Pneumonia","completionDate":"2024-04-12"},{"nctId":"NCT03245879","phase":"NA","title":"Impact of Implementing Antibiotic Stewardship Programs in 15 Small Hospitals: A Cluster-Randomized Trial Intervention","status":"COMPLETED","sponsor":"Intermountain Health Care, Inc.","isPivotal":false,"enrollment":30000,"indication":"Inappropriate Prescribing, Antibiotic Stewardship","completionDate":"2015-06"},{"nctId":"NCT06748144","phase":"Phase 2","title":"Intraosseous vs. Intravenous Vancomycin Administration in Spine Surgery","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","isPivotal":true,"enrollment":30,"indication":"Lumbar Fusion Surgery","completionDate":"2030-04"},{"nctId":"NCT05106803","phase":"N/A","title":"Antibiotic Profile of Pathogenic Bacteria Isolated From Postsurgical Site Infections in Public Hospitals in Northern Jordan","status":"COMPLETED","sponsor":"Yarmouk University","isPivotal":false,"enrollment":24,"indication":"Bacterial Infections, Antibiotic Resistant Infection","completionDate":"2019-10-01"},{"nctId":"NCT02123628","phase":"Phase 4","title":"Six- Versus Twelve-Week Therapy for Non-Surgically-Treated Diabetic Foot Osteomyelitis: A Multicenter Open-Label Controlled Randomized Study","status":"COMPLETED","sponsor":"Tourcoing Hospital","isPivotal":false,"enrollment":40,"indication":"Diabetes Mellitus","completionDate":"2012-09"},{"nctId":"NCT02680600","phase":"NA","title":"Pharmacokinetic Evaluation of Cefepime Administrered Intravenously in Intensive Care Patients","status":"COMPLETED","sponsor":"Onze Lieve Vrouw Hospital","isPivotal":false,"enrollment":20,"indication":"Antimicrobial Treatment","completionDate":"2016-01"},{"nctId":"NCT07484633","phase":"Phase 4","title":"A Protocol of a Randomised, Two-arm Superiority Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients","status":"NOT_YET_RECRUITING","sponsor":"Semmelweis University","isPivotal":false,"enrollment":110,"indication":"Infection, Sepsis","completionDate":"2028-04"},{"nctId":"NCT05905055","phase":"Phase 3","title":"A Phase 3, Multi-Center, Randomized, Single-Blind Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Urina","status":"COMPLETED","sponsor":"Meiji Seika Pharma Co., Ltd.","isPivotal":true,"enrollment":126,"indication":"Complicated Urinary Tract Infection, Acute Pyelonephritis","completionDate":"2025-09-01"},{"nctId":"NCT04278404","phase":"N/A","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs","status":"RECRUITING","sponsor":"Duke University","isPivotal":false,"enrollment":5000,"indication":"Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension","completionDate":"2027-07"},{"nctId":"NCT06168734","phase":"Phase 3","title":"A Phase 3 Study to Evaluate Cefepime-taniborbactam Compared to Meropenem in Adults With Ventilator Associated Bacterial Pneumonia (VABP) or Ventilated Hospital Acquired Bacterial Pneumonia (vHABP)","status":"WITHDRAWN","sponsor":"Venatorx Pharmaceuticals, Inc.","isPivotal":true,"enrollment":0,"indication":"Ventilator-associated Pneumonia, Hospital-acquired Pneumonia","completionDate":"2027-12"},{"nctId":"NCT02872038","phase":"Phase 4","title":"A Multicenter, Randomized, Controlled Trial Comparing Cefepime Monotherapy Versus Combination of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-associated Peritonitis","status":"COMPLETED","sponsor":"Chulalongkorn University","isPivotal":false,"enrollment":154,"indication":"Peritoneal Dialysis Associated Peritonitis","completionDate":"2016-11-30"},{"nctId":"NCT03078010","phase":"Phase 2","title":"Rational Use of Broad-spectrum Antibiotics as Empiric Antibiotic Therapy in Febrile Neutropenia in Recipients of Allogeneic Hematopoietic Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","isPivotal":false,"enrollment":347,"indication":"Intestinal Microbiome, Febrile Neutropenia","completionDate":"2027-02"},{"nctId":"NCT05094154","phase":"Phase 4","title":"Effect of Antibiotic Choice On ReNal Outcomes (ACORN)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","isPivotal":false,"enrollment":2634,"indication":"Sepsis, AKI","completionDate":"2022-10-21"},{"nctId":"NCT01793012","phase":"N/A","title":"Drug Monitoring of Antibiotics in Critical Care Patients","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","isPivotal":false,"enrollment":186,"indication":"ARDS, Sepsis","completionDate":"2015-01"},{"nctId":"NCT03790631","phase":"N/A","title":"The OPTIMAL TDM Study: Determining Optimal Beta-lactam Plasma Concentrations Through Therapeutic Drug Monitoring","status":"COMPLETED","sponsor":"University of Geneva, Switzerland","isPivotal":false,"enrollment":771,"indication":"Beta-lactam Antibiotics, Therapeutic Drug Monitoring","completionDate":"2023-12-31"},{"nctId":"NCT02581280","phase":"N/A","title":"Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Meropenem, Vancomycin, Remifentanil, Cefepime, Cefpirome, Sufentanil, Midazolam, Clopidogrel, Ticagrelor, Prasugrel D","status":"COMPLETED","sponsor":"Yonsei University","isPivotal":false,"enrollment":56,"indication":"Cardiac Dysfunction","completionDate":"2019-01-31"},{"nctId":"NCT06406114","phase":"Phase 2","title":"Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing","status":"RECRUITING","sponsor":"Massachusetts General Hospital","isPivotal":false,"enrollment":300,"indication":"Drug Allergy, Cephalosporin Allergy","completionDate":"2028-12-31"},{"nctId":"NCT00044759","phase":"Phase 3","title":"A Randomized, Open-Label, Multi-Center, Comparative Study of the Efficacy and Safety of Piperacillin/Tazobactam to Cefepime for the Empiric Treatment of Neutropenic Fever in Patients With a Hematologi","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","isPivotal":true,"enrollment":0,"indication":"Hematologic Neoplasms","completionDate":"2003-01"},{"nctId":"NCT03147807","phase":"NA","title":"BetaLACTA® Test-guided Early De-escalation of Empirical Carbapenems in Pulmonary, Urinary and Bloodstream Infections Diagnosed in Intensive Care Unit - BLUE¬-CarbA Study","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","isPivotal":false,"enrollment":75,"indication":"Pneumonia, Urinary Tract Infections","completionDate":"2019-10-20"},{"nctId":"NCT03638830","phase":"Phase 2","title":"Randomized, Blind, Placebo-controlled Study to Evaluate Safety and Efficacy of Ftortiazinon in Combination With Maxipime®, in Comparison With Placebo in Combination With Maxipime®, in the Treatment of","status":"COMPLETED","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","isPivotal":false,"enrollment":777,"indication":"Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa, Pseudomonas Aeruginosa","completionDate":"2022-11-23"},{"nctId":"NCT03680352","phase":"Phase 1","title":"Phase 1, Open-label, Parallel Group, Single-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AAI101 With Cefepime in Subjects With Varying Degrees of Renal Function","status":"COMPLETED","sponsor":"Allecra","isPivotal":false,"enrollment":30,"indication":"PK in Patients With Various Degrees of Renal Impairment","completionDate":"2018-12-30"},{"nctId":"NCT03680378","phase":"Phase 1","title":"A Phase I Open-Label, Single-Centre Study to Assess the Concentration of AAI101 and Cefepime in Epithelial Lining Fluid and Plasma in Healthy Volunteers","status":"COMPLETED","sponsor":"Allecra","isPivotal":false,"enrollment":19,"indication":"Healthy Subjects","completionDate":"2019-04-30"},{"nctId":"NCT04948463","phase":"Phase 4","title":"Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","isPivotal":false,"enrollment":55,"indication":"Febrile Neutropenia","completionDate":"2025-12-17"},{"nctId":"NCT04033029","phase":"N/A","title":"Antibiotic Plasma Concentrations During Continuous Renal Replacement Therapy With a High Adsorption Membrane (oXiris®)","status":"COMPLETED","sponsor":"Hospital Universitari de Bellvitge","isPivotal":false,"enrollment":20,"indication":"Hemodiafiltration, Sepsis","completionDate":"2023-06-30"},{"nctId":"NCT01667094","phase":"Phase 4","title":"Continuous-infusion Anti-pseudomonal β-lactams for the Treatment of Acute, Infective Pulmonary Exacerbations in Cystic Fibrosis","status":"UNKNOWN","sponsor":"The Alfred","isPivotal":false,"enrollment":50,"indication":"Cystic Fibrosis","completionDate":"2017-07"},{"nctId":"NCT02732327","phase":"Phase 2","title":"A Single-Center, Randomized, Open-label, Prospective, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI) Plus Vancomycin or Linezolid Versus Stand","status":"TERMINATED","sponsor":"Forest Laboratories","isPivotal":false,"enrollment":2,"indication":"Neoplasms, Febrile Neutropenia","completionDate":"2016-06-27"},{"nctId":"NCT03622008","phase":"Phase 1","title":"A Phase 1, Randomized, Double-Blind Study to Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ) After Intravenous Administrations in Healthy Volunteers","status":"COMPLETED","sponsor":"Wockhardt","isPivotal":false,"enrollment":20,"indication":"Antibiotics Causing Adverse Effects in Therapeutic Use","completionDate":"2018-05-30"},{"nctId":"NCT02302092","phase":"Phase 3","title":"A Phase 3, Randomized, Double-blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous Infusions of Flomoxef Versus Intravenous Infusions of Cefepime in the Treatment of Subjects With","status":"TERMINATED","sponsor":"Takeda","isPivotal":true,"enrollment":13,"indication":"Urinary Tract Infection","completionDate":"2016-12-15"},{"nctId":"NCT01110408","phase":"Phase 3","title":"A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infectio","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","isPivotal":true,"enrollment":41,"indication":"Complicated Urinary Tract Infections or Pyelonephritis","completionDate":"2013-06"},{"nctId":"NCT00609375","phase":"Phase 4","title":"Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen in Adult Critically Ill Patients With Gram Negative Bacilli Bacteremia","status":"COMPLETED","sponsor":"Javeriana University","isPivotal":false,"enrollment":30,"indication":"Sepsis, Bacteremia","completionDate":"2007-12"},{"nctId":"NCT00358202","phase":"Phase 4","title":"Phase 4 Study of Once-Daily Intramuscular Cefepime Versus Ceftriaxone for In-Home Treatment of Nursing Home-Acquired Pneumonia","status":"COMPLETED","sponsor":"CPL Associates","isPivotal":false,"enrollment":69,"indication":"Pneumonia","completionDate":"2006-04"},{"nctId":"NCT05705843","phase":"Phase 4","title":"Intraosseous Vancomycin vs Intravenous Vancomycin in Tourniquetless Primary Total Knee Arthroplasty","status":"UNKNOWN","sponsor":"The Methodist Hospital Research Institute","isPivotal":false,"enrollment":40,"indication":"Infection, Surgical Site","completionDate":"2024-01-25"},{"nctId":"NCT03685084","phase":"Phase 1","title":"Phase I, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of AAI101 Administered Intravenously Alone or in Combination With Piperacillin or Cefepim","status":"COMPLETED","sponsor":"Allecra","isPivotal":false,"enrollment":56,"indication":"Healthy","completionDate":"2014-01-13"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}